Renovaro Inc.

Equities

RENB

US29350E1047

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
1.45 ^USD	0.00%		-9.38%	-54.26%

Jul. 03	Renovaro Inc. Announces Resignation of Leni Boeren as Member of the Board of Directors	CI
Jul. 01	Renovaro Inc.(NasdaqCM:RENB) added to Russell Small Cap Comp Value Index	CI

ENOCHIAN BIOSCIENCES INC : Other Events (form 8-K)

January 24, 2022 at 03:02 pm EST

Item 8.01. Other Events.

On January 24, 2022, Enochian Biosciences Inc. (the "Company") issued a shareholder letter (the "Shareholder Letter") providing updates on clinical progress and business development. A copy of the Shareholder Letter is attached hereto as Exhibit 99.1, and is incorporated herein by reference.

Latest news about Renovaro Inc.

Renovaro Inc. Announces Resignation of Leni Boeren as Member of the Board of Directors	Jul. 03	CI
Renovaro Inc.(NasdaqCM:RENB) added to Russell Small Cap Comp Value Index	Jun. 30	CI
Renovaro Inc.(NasdaqCM:RENB) added to Russell Small Cap Completeness Index	Jun. 30	CI
Renovaro Inc.(NasdaqCM:RENB) added to Russell 3000 Value Index	Jun. 30	CI
Renovaro Inc.(NasdaqCM:RENB) added to Russell 2000 Index	Jun. 30	CI
Renovaro Inc.(NasdaqCM:RENB) added to Russell 3000E Index	Jun. 30	CI
Renovaro Inc.(NasdaqCM:RENB) added to Russell 2500 Value Index	Jun. 30	CI
Renovaro Inc.(NasdaqCM:RENB) added to Russell 3000 Growth Index	Jun. 30	CI
Renovaro Inc.(NasdaqCM:RENB) added to Russell 2000 Value Index	Jun. 30	CI
Renovaro Inc.(NasdaqCM:RENB) added to Russell 3000E Growth Index	Jun. 30	CI
Renovaro Inc.(NasdaqCM:RENB) added to Russell 2000 Growth Index	Jun. 30	CI
Renovaro Inc.(NasdaqCM:RENB) added to Russell 2000 Dynamic Index	Jun. 30	CI
Renovaro Inc.(NasdaqCM:RENB) added to Russell 2500 Growth Index	Jun. 30	CI
Renovaro Inc.(NasdaqCM:RENB) added to Russell Small Cap Comp Growth Index	Jun. 30	CI
Renovaro Inc.(NasdaqCM:RENB) added to Russell 2500 Index	Jun. 30	CI
Renovaro Inc.(NasdaqCM:RENB) added to Russell 3000 Index	Jun. 30	CI
Renovaro Inc.(NasdaqCM:RENB) added to Russell 3000E Value Index	Jun. 30	CI
Renovaro Says Investors Commit $10 Million Additional Equity	Jun. 14	MT
Renovaro Inc. announced that it has received $9.455942 million in funding	Jun. 13	CI
Renovaro, Amsterdam UMC Cancer Center Plan to Form Joint Venture for Cancer Immunotherapy	May. 24	MT
Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy	May. 24	CI
Renovaro Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	May. 15	CI
Renovaro's RenovaroCube Amends Agreement to Acquire 100% Stake in Cyclomics	Apr. 24	MT
Renovaro Inc. Announces Geert Kazemier, MD, PhD, as the New Chairman of its Scientific Advisory Board	Apr. 18	CI
Renovaro Inc. Appoints Simon Tarsh as Interim Chief Financial Officer	Mar. 13	CI

Chart Renovaro Inc.

Duration

Period

More charts

Company Profile

Renovaro Inc., formerly Renovaro BioSciences Inc., is a biotechnology company. The Company is engaged in the research and development of pharmaceutical and biological products for the treatment of cancer, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. The Company has a single product candidate as a potential cure for HIV, RENB-HV01, adding two additional pipeline candidates for HIV, RENB-HV12 and RENB-HV21, a pipeline for HBV, RENB-HB01, and with a significant into cancer immune therapies to address high unmet needs from difficult-to-treat solid tumors, RENB-DC11. RENB-HV-01 is a HIV autologous transplant with genetically modified cells. RENB-HV12 is a HIV therapeutic vaccine for potential long-term remission/cure. RENB-HV-21, a treatment for HIV with allogenic Natural Killer (NK) and Gamma Delta T-Cells (GDT). RENB-HB-01 is an HBV gene therapy candidate.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
RENOVARO INC.	-54.26%	214M
VERTEX PHARMACEUTICALS INCORPORATED	+20.12%	126B
REGENERON PHARMACEUTICALS, INC.	+25.25%	119B
ARGENX SE	+25.56%	27.95B
BIONTECH SE	-19.51%	20.5B
GENMAB A/S	-14.36%	17.12B
BEIGENE, LTD.	-15.63%	16.1B
WUXI APPTEC CO., LTD.	-46.67%	14.97B
NEUROCRINE BIOSCIENCES, INC.	+11.89%	14.84B
SAREPTA THERAPEUTICS, INC.	+57.74%	14.38B

Bio Therapeutic Drugs